Quick Answer
Xilio Therapeutics, Inc. reported Net Income Loss of -$35.04 million for the year ending 2025.
- Xilio Therapeutics, Inc. showed an increase of +39.8% in Net Income Loss from 2024 to 2025.
- This data is from Xilio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Xilio Therapeutics, Inc.'s Net Income Loss has grown by 36.6%.
- Historical annual values: Fiscal year 2025: -$35.04 million | Fiscal year 2024: -$58.24 million | Fiscal year 2023: -$76.40 million | Fiscal year 2022: -$88.22 million | Fiscal year 2021: -$75.80 million | Fiscal year 2020: -$55.22 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: